302 related articles for article (PubMed ID: 30797052)
21. Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance.
Eliyahu S; Sharabi O; Elmedvi S; Timor R; Davidovich A; Vigneault F; Clouser C; Hope R; Nimer A; Braun M; Weiss YY; Polak P; Yaari G; Gal-Tanamy M
Front Immunol; 2018; 9():3004. PubMed ID: 30622532
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
[TBL] [Abstract][Full Text] [Related]
23. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
[TBL] [Abstract][Full Text] [Related]
24. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
[TBL] [Abstract][Full Text] [Related]
26. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies.
Beld M; Penning M; van Putten M; van den Hoek A; Lukashov V; McMorrow M; Goudsmit J
J Clin Microbiol; 1998 Oct; 36(10):3002-6. PubMed ID: 9738057
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.
Osburn WO; Fisher BE; Dowd KA; Urban G; Liu L; Ray SC; Thomas DL; Cox AL
Gastroenterology; 2010 Jan; 138(1):315-24. PubMed ID: 19782080
[TBL] [Abstract][Full Text] [Related]
29. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
[TBL] [Abstract][Full Text] [Related]
30. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
31. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
Meunier JC; Gottwein JM; Houghton M; Russell RS; Emerson SU; Bukh J; Purcell RH
J Infect Dis; 2011 Oct; 204(8):1186-90. PubMed ID: 21917891
[TBL] [Abstract][Full Text] [Related]
32. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.
Zhang P; Zhong L; Struble EB; Watanabe H; Kachko A; Mihalik K; Virata ML; Alter HJ; Feinstone S; Major M
Proc Natl Acad Sci U S A; 2009 May; 106(18):7537-41. PubMed ID: 19380744
[TBL] [Abstract][Full Text] [Related]
33. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
[TBL] [Abstract][Full Text] [Related]
34. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
35. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user.
Aitken CK; Tracy SL; Revill P; Bharadwaj M; Bowden DS; Winter RJ; Hellard ME
J Clin Virol; 2008 Apr; 41(4):293-6. PubMed ID: 18242125
[TBL] [Abstract][Full Text] [Related]
36. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
von Hahn T; Yoon JC; Alter H; Rice CM; Rehermann B; Balfe P; McKeating JA
Gastroenterology; 2007 Feb; 132(2):667-78. PubMed ID: 17258731
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
[TBL] [Abstract][Full Text] [Related]
39. Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies.
Beaumont E; Joël Clément B; Guérin V; Chopin L; Roch E; Gomez-Escobar E; Roingeard P
Liver Int; 2020 Aug; 40(8):1865-1871. PubMed ID: 32458507
[TBL] [Abstract][Full Text] [Related]
40. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
